A graphical representation verifying the binding strength between the antibodies designed by GaluxDesign and each therapeutic ...

EGFR(S468R), ACVR2A/B, FZD7, and ALK7. Notably, the team successfully designed antibodies targeting ALK7, a protein without an experimentally resolved structure, as well as antibodies targeting a ...